Crinetics Pharmaceuticals, Inc.
General ticker "CRNX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.3B (TTM average)
Crinetics Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 52.0%.
Estimated limits based on current volatility of 2.4%: low 38.59$, high 40.47$
Factors to consider:
- Total employees count: 437 (+50.7%) as of 2024
- Top business risk factors: Financing risks, Geopolitical risks, Labor/talent shortage/retention, Operational and conduct risks, Pandemic risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [33.54$, 65.19$]
- 2026-12-31 to 2027-12-31 estimated range: [27.84$, 56.08$]
Financial Metrics affecting the CRNX estimates:
- Negative: with PPE of -9.6 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -8.42 <= 0.01
- Positive: Investing cash flow per share per price, % of 3.88 > -0.63
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 88.09 > 64.29
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term CRNX quotes
Long-term CRNX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $4.01MM | $1.04MM | $5.42MM |
| Operating Expenses | $226.62MM | $339.89MM | $522.19MM |
| Operating Income | $-222.61MM | $-338.85MM | $-516.77MM |
| Non-Operating Income | $8.08MM | $40.45MM | $51.63MM |
| R&D Expense | $168.53MM | $240.16MM | $332.06MM |
| Income(Loss) | $-214.53MM | $-298.41MM | $-465.14MM |
| Taxes | $0.00MM | $0.00MM | $0.18MM |
| Profit(Loss)* | $-214.53MM | $-298.41MM | $-465.32MM |
| Stockholders Equity | $539.11MM | $1,324.81MM | $992.08MM |
| Inventory | $0.00MM | $0.00MM | $2.02MM |
| Assets | $635.35MM | $1,434.59MM | $1,126.26MM |
| Operating Cash Flow | $-166.31MM | $-225.97MM | $-377.92MM |
| Capital expenditure | $4.69MM | $3.84MM | $5.76MM |
| Investing Cash Flow | $-200.41MM | $-574.82MM | $173.91MM |
| Financing Cash Flow | $388.94MM | $1,010.43MM | $40.61MM |
| Earnings Per Share** | $-3.69 | $-3.69 | $-4.95 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.